More participants in the higher-dose group than placebo achieved an HbA1c under 7% (55.9% vs 15.2%) or under 6.5% (29.4% vs 6 ...

Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...

California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...

Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships.

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

The versatile rare diseases drug venglustat came from Sanofi ... disease is likely to play well with investors. Sanofi’s decision to axe diabetes R&D means that it will end development of ...

With a market valuation of Rs 11,574.76 Cr, Sanofi Indias shares ended Fridays trading session on the BSE 0.58% higher at Rs ...

The US FDA has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes.

Sanofi-Synthélabo is known for creating meningitis treatment, Menactra, diabetes treatment Lantus, colorectal cancer drug Eloxatin, and lung, prostate and breast cancer drug Taxorete. While this ...